Peter Joyce

Company: Grey Wolf Therapeutics Ltd.

Seminars:

Targeting ERAP1: Altering Neoantigen Presentation With a Small Molecule 1:00 pm

Tumor visibility, defined as the level of tumor-specific antigen expression, is shown to strongly correlate with response to checkpoint inhibition and is a vital aspect determining the immunogenicity within the tumor microenvironment Grey Wolf have developed inhibitors of ERAP1, an aminopeptidase in the antigen presentation pathway that determines which antigens are presented on the surface…Read more

day: Day One